pharmexec.com
Cure8 news brief
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
Medications
Mirikizumab
IL-23 inhibitor
Abdominal Pain
Urgency
Regulatory Update
Adult patients
Patients On Biologics
Why This Matters
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus placebo. This may affect treatment discussions between patients and clinicians.
Who Should Pay Attention
Adults with moderate-to-severe Crohn disease, patients considering biologic therapy, clinicians treating IBD, and researchers following new IBD drug approvals.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
Omvoh is a biologic (mirikizumab) now approved for both ulcerative colitis and Crohn disease. The VIVID-1 trial used a 900 mg IV induction at weeks 0, 4, and 8, followed by 300 mg SC every 4 weeks starting at week 12; the FDA decision cited clinical remission and endoscopic response at one year as primary endpoints.
Safety findings in the Crohn’s studies were reported as consistent with the drug’s prior ulcerative colitis profile, with common events including upper respiratory infections, injection-site reactions, headache, arthralgia, and elevated liver tests.
For people tracking new treatment options: this approval adds another biologic class option for adults with moderate-to-severe Crohn disease and may be relevant for patients who have not responded to other therapies. Ongoing VIVID-2 will provide longer-term safety and efficacy data.
Keep In Mind
This is a regulatory approval story based on Phase III VIVID-1 results and company/release citations; full prescribing information, longer-term data from the VIVID-2 extension, and independent peer-reviewed publications should be consulted for detailed efficacy and safety characteristics.
The article summarizes press-release information and trial endpoints rather than presenting new independent analyses.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationpharmexec.com
Indexed viaBing News
Source typeResearch news
PublishedJan 16, 2025, 9:24 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.